CL2014003326A1 - Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. - Google Patents
Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene.Info
- Publication number
- CL2014003326A1 CL2014003326A1 CL2014003326A CL2014003326A CL2014003326A1 CL 2014003326 A1 CL2014003326 A1 CL 2014003326A1 CL 2014003326 A CL2014003326 A CL 2014003326A CL 2014003326 A CL2014003326 A CL 2014003326A CL 2014003326 A1 CL2014003326 A1 CL 2014003326A1
- Authority
- CL
- Chile
- Prior art keywords
- repertfusion
- deferoxamine
- acetylcysteine
- injectable
- kit
- Prior art date
Links
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 title 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 title 1
- 229960004308 acetylcysteine Drugs 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 238000002399 angioplasty Methods 0.000 title 1
- 239000003963 antioxidant agent Substances 0.000 title 1
- 230000003078 antioxidant effect Effects 0.000 title 1
- 235000006708 antioxidants Nutrition 0.000 title 1
- 230000000747 cardiac effect Effects 0.000 title 1
- 229960000958 deferoxamine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 238000001990 intravenous administration Methods 0.000 title 1
- 229940075525 iron chelating agent Drugs 0.000 title 1
- 239000000797 iron chelating agent Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002107 myocardial effect Effects 0.000 title 1
- 239000007800 oxidant agent Substances 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 title 1
- 229940124531 pharmaceutical excipient Drugs 0.000 title 1
- 235000010378 sodium ascorbate Nutrition 0.000 title 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 title 1
- 229960005055 sodium ascorbate Drugs 0.000 title 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/18—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient
- B65D81/20—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents providing specific environment for contents, e.g. temperature above or below ambient under vacuum or superatmospheric pressure, or in a special atmosphere, e.g. of inert gas
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/30—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants by excluding light or other outside radiation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2014003326A CL2014003326A1 (es) | 2014-12-05 | 2014-12-05 | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. |
| PCT/CL2015/050048 WO2016086327A1 (es) | 2014-12-05 | 2015-12-04 | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, n-acetilcisteína, y deferoxamina; método de administración y uso en prevenir daño por reperfusión; y kit |
| US15/532,556 US20170333393A1 (en) | 2014-12-05 | 2015-12-04 | Injectable antioxidant formulation for intravenous use of sodium ascorbate in high dosage, n-acetyl cysteine, and deferoxamine; method of administration and use for preventing injury due to reperfusion; and kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2014003326A CL2014003326A1 (es) | 2014-12-05 | 2014-12-05 | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003326A1 true CL2014003326A1 (es) | 2015-03-20 |
Family
ID=53404099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003326A CL2014003326A1 (es) | 2014-12-05 | 2014-12-05 | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20170333393A1 (es) |
| CL (1) | CL2014003326A1 (es) |
| WO (1) | WO2016086327A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018503689A (ja) | 2015-01-27 | 2018-02-08 | フローレンゲイル・エル・エル・シー | 治癒性局所用組成物 |
| GR20180100514A (el) * | 2018-11-07 | 2020-06-15 | Πανεπιστημιο Πατρων | Φαρμακευτικοι συνδυασμοι και κιτ για την προληψη ή την θεραπεια του πονου και αλλων επιπλοκων της ορθοπαιδικης ή αγγειακης χειρουργικης και του πολλαπλου τραυματος |
-
2014
- 2014-12-05 CL CL2014003326A patent/CL2014003326A1/es unknown
-
2015
- 2015-12-04 US US15/532,556 patent/US20170333393A1/en not_active Abandoned
- 2015-12-04 WO PCT/CL2015/050048 patent/WO2016086327A1/es active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016086327A1 (es) | 2016-06-09 |
| US20170333393A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001433A1 (es) | Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684) | |
| DOP2016000233A (es) | MODULADORES ALOSTÉRICOS DE PROTElNA NÚCLEO DE HEPATITIS B | |
| CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
| GT201700167A (es) | Terapias de combinación para el tratamiento de cánceres. | |
| CR20170424A (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb | |
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| CL2019003589A1 (es) | Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer. | |
| NI201600115A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
| CL2017000156A1 (es) | Procedimientos para el tratamiento de paramixovirus. | |
| CR20160200A (es) | Combinaciones de inhibidores de histona desacetilasa y fármacos inmunomoduladores | |
| DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
| MX2017008486A (es) | Combinaciones del inhibidor de tirosina cinasa de bruton (btk) y regimenes de dosificacion. | |
| CO7461127A2 (es) | Código para la configuración de un dispositivo de atención al paciente | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| CO2018000768A2 (es) | Administración intravenosa de citrulina durante la cirugía | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| CL2014003326A1 (es) | Formulación antioxidante inyectable de uso intravenoso de ascorbato de sodio - en altas dosis, y n-acetilcisteína como agentes oxidantes, y deferoxamina como agentes quelante de hierro, más excipientes farmacéuticos; método para su administración y uso en prevenir el daño por repertfusión en pacientes con inferto agudo del miocardío, sometidos a angioplastia caronaria primaria; y kit que la contiene. |